All Cosmos Bio-Tech Holding Corp
All Cosmos Bio-Tech Holding Corporation, through its subsidiaries, manufactures and sells bio-organic and bio-chemical compound fertilizers in Malaysia and internationally. The company offers bio-chemical fertilizers, as well as offers water reutilization services. It also engages in the research and development of microorganisms for waste disposal of oil-palm; and wholesale of probiotics. In add… Read more
All Cosmos Bio-Tech Holding Corp (4148) - Net Assets
Latest net assets as of September 2025: NT$3.18 Billion TWD
Based on the latest financial reports, All Cosmos Bio-Tech Holding Corp (4148) has net assets worth NT$3.18 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.88 Billion) and total liabilities (NT$698.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.18 Billion |
| % of Total Assets | 82.01% |
| Annual Growth Rate | 11.09% |
| 5-Year Change | 32.46% |
| 10-Year Change | 119.54% |
| Growth Volatility | 15.54 |
All Cosmos Bio-Tech Holding Corp - Net Assets Trend (2010–2024)
This chart illustrates how All Cosmos Bio-Tech Holding Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for All Cosmos Bio-Tech Holding Corp (2010–2024)
The table below shows the annual net assets of All Cosmos Bio-Tech Holding Corp from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.13 Billion | +11.23% |
| 2023-12-31 | NT$2.81 Billion | -1.71% |
| 2022-12-31 | NT$2.86 Billion | +20.37% |
| 2021-12-31 | NT$2.38 Billion | +0.65% |
| 2020-12-31 | NT$2.36 Billion | -2.59% |
| 2019-12-31 | NT$2.43 Billion | -4.34% |
| 2018-12-31 | NT$2.54 Billion | +8.13% |
| 2017-12-31 | NT$2.35 Billion | +50.57% |
| 2016-12-31 | NT$1.56 Billion | +9.24% |
| 2015-12-31 | NT$1.43 Billion | +1.47% |
| 2014-12-31 | NT$1.41 Billion | +21.39% |
| 2013-12-31 | NT$1.16 Billion | -2.83% |
| 2012-12-31 | NT$1.19 Billion | +31.93% |
| 2011-12-31 | NT$903.04 Million | +25.73% |
| 2010-12-31 | NT$718.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to All Cosmos Bio-Tech Holding Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 761.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$652.14 Million | 25.93% |
| Common Stock | NT$640.34 Million | 25.46% |
| Other Components | NT$1.22 Billion | 48.61% |
| Total Equity | NT$2.52 Billion | 100.00% |
All Cosmos Bio-Tech Holding Corp Competitors by Market Cap
The table below lists competitors of All Cosmos Bio-Tech Holding Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ONCOTHERAPY SCIENCE INC.
F:30O
|
$32.63 Million |
|
Tsann Kuen Enterprise Co Ltd
TW:2430
|
$32.65 Million |
|
JF Technology BHD
KLSE:0146
|
$32.65 Million |
|
FnGuide Inc.
KQ:064850
|
$32.66 Million |
|
GIIR Inc
KO:035000
|
$32.62 Million |
|
Helios Energy Limited
PINK:HLEGF
|
$32.60 Million |
|
Vicapsys Life Sciences Inc
PINK:VICP
|
$32.59 Million |
|
Tae Kyung Ind
KO:015890
|
$32.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in All Cosmos Bio-Tech Holding Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,254,343,000 to 2,515,235,000, a change of 260,892,000 (11.6%).
- Net income of 128,588,000 contributed positively to equity growth.
- Dividend payments of 64,034,000 reduced retained earnings.
- Other comprehensive income decreased equity by 147,942,999.
- Other factors increased equity by 344,280,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$128.59 Million | +5.11% |
| Dividends Paid | NT$64.03 Million | -2.55% |
| Other Comprehensive Income | NT$-147.94 Million | -5.88% |
| Other Changes | NT$344.28 Million | +13.69% |
| Total Change | NT$- | 11.57% |
Book Value vs Market Value Analysis
This analysis compares All Cosmos Bio-Tech Holding Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.52x to 1.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | NT$16.70 | NT$42.15 | x |
| 2012-12-31 | NT$20.92 | NT$42.15 | x |
| 2013-12-31 | NT$20.82 | NT$42.15 | x |
| 2014-12-31 | NT$24.72 | NT$42.15 | x |
| 2015-12-31 | NT$21.81 | NT$42.15 | x |
| 2016-12-31 | NT$23.29 | NT$42.15 | x |
| 2017-12-31 | NT$33.45 | NT$42.15 | x |
| 2018-12-31 | NT$33.82 | NT$42.15 | x |
| 2019-12-31 | NT$31.91 | NT$42.15 | x |
| 2020-12-31 | NT$30.98 | NT$42.15 | x |
| 2021-12-31 | NT$31.00 | NT$42.15 | x |
| 2022-12-31 | NT$35.84 | NT$42.15 | x |
| 2023-12-31 | NT$31.86 | NT$42.15 | x |
| 2024-12-31 | NT$38.88 | NT$42.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently All Cosmos Bio-Tech Holding Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.11%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.23%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.46x
- Recent ROE (5.11%) is below the historical average (12.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 19.46% | 11.56% | 1.07x | 1.58x | NT$78.92 Million |
| 2012 | 20.13% | 11.66% | 0.98x | 1.76x | NT$105.85 Million |
| 2013 | 15.23% | 8.45% | 0.96x | 1.87x | NT$54.41 Million |
| 2014 | 15.21% | 8.77% | 0.94x | 1.84x | NT$67.00 Million |
| 2015 | 15.96% | 8.73% | 0.96x | 1.90x | NT$73.60 Million |
| 2016 | 18.25% | 11.77% | 0.98x | 1.59x | NT$109.93 Million |
| 2017 | 15.84% | 14.26% | 0.84x | 1.32x | NT$118.98 Million |
| 2018 | 14.04% | 11.35% | 0.90x | 1.37x | NT$87.82 Million |
| 2019 | 1.74% | 2.02% | 0.67x | 1.29x | NT$-168.88 Million |
| 2020 | 4.14% | 5.00% | 0.63x | 1.32x | NT$-116.45 Million |
| 2021 | 9.95% | 9.02% | 0.74x | 1.49x | NT$-908.60K |
| 2022 | 15.56% | 9.95% | 0.90x | 1.74x | NT$131.51 Million |
| 2023 | 6.18% | 4.93% | 0.77x | 1.63x | NT$-86.07 Million |
| 2024 | 5.11% | 5.23% | 0.67x | 1.46x | NT$-122.94 Million |
Industry Comparison
This section compares All Cosmos Bio-Tech Holding Corp's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $16,328,589,500
- Average return on equity (ROE) among peers: 7.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| All Cosmos Bio-Tech Holding Corp (4148) | NT$3.18 Billion | 19.46% | 0.22x | $32.62 Million |
| Sinon Corp (1712) | $7.11 Billion | 10.07% | 1.10x | $442.00 Million |
| Taiwan Fertilizer Co Ltd (1722) | $54.27 Billion | 1.72% | 0.50x | $922.26 Million |
| Huikwang (6508) | $2.45 Billion | 13.42% | 0.30x | $40.53 Million |
| CH Biotech R&D Co., Ltd. (6534) | $1.48 Billion | 6.77% | 0.95x | $93.83 Million |